Prospective, Multi-Center Clinical Outcomes Study Evaluating the chronOS Strip Combined With Bone Marrow Aspirate

Not Applicable

Completed

• Conditions: Degeneration of Lumbar Intervertebral Disc
• Interventions: Device: chronOS Strip

• Registration Number: NCT00943384
• Lead Sponsor: Synthes USA HQ, Inc.

Brief Summary

The chronOS Strip is a synthetic bone void filler manufactured from chronOS beta-tricalcium phosphate (β-TCP) granules and a resorbable polymer \[poly(lactide co-ε-caprolactone)\]. The chronOS Strip, combined with autogenous bone and/or bone marrow or autograft, is intended to be used in the spine for posterolateral fusion.

The purpose of this prospective, multi-center clinical case series was to evaluate posterolateral fusion rates in a prospective series of patients with degenerative disc disease. The surgical procedure consisted of instrumented posterolateral fusion with interbody support. The chronOS Strip, combined with bone marrow aspirate and local bone, was applied to the posterolateral gutters.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-07
• Study First Submitted: 2009-07-21
• Study First Submitted QC: 2009-07-21
• Study First Posted: 2009-07-22
• Primary Completion: 2013-10
• Study Completion: 2013-10
• Results First Submitted: 2014-10-21
• Status Verified: 2014-11
• Results First Submitted QC: 2014-11-18
• Last Update Submitted: 2014-11-18
• Results First Posted: 2014-11-26
• Last Update Posted: 2014-11-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

1. Has the following indication for posterolateral fusion (transverse process and facet fusion) with posterior rod and screw fixation:

   • Degenerative Disc Disease (DDD), with or without stenosis. Diagnosis of DDD requires back and/or leg (radicular) pain along with:

   1. Instability (≥ 3 mm translation or ≥ 5° angulation); or
   2. MRI confirmation of Modic Type 1 or Type 2 changes; or
   3. High intensity zones in the disc space.

2. Has one or two motion segment(s) to be fused between L2 and S1;

3. Skeletally mature adult, at least 18 years of age at the time of surgery;

4. Oswestry Low Back Pain Disability Questionnaire score ≥ 30 (out of 100);

5. Has completed at least 6 months of conservative therapy, which may include physical therapy, bracing, systemic or injected medications;

6. Psychosocially, mentally and physically able to fully comply with this protocol including adhering to scheduled visits, treatment plan, completing forms, and other study procedures;

7. Personally signed and dated informed consent document prior to any study-related procedures indicating that the patient has been informed of all pertinent aspects of the study.

Exclusion Criteria

1. Three or more motion segments to be fused;
2. Degenerative scoliosis, defined as Cobb angle > 10° at any level in lumbar spine;
3. Has had a previous interbody fusion or posterolateral fusion attempt at any level of the lumbar spine;
4. Active systemic or local infection;
5. Known or documented history of communicable disease, including AIDS and HIV;
6. Active Hepatitis (receiving medical treatment within two years);
7. Active rheumatoid arthritis, non-controlled diabetes mellitus, or any other medical condition(s) that would represent a significant increase in surgical risk or interfere with normal healing;
8. Immunologically suppressed, or has received systemic steroids, excluding nasal steroids, at any dose daily for > 1 month within last 12 months;
9. Known history of Paget's disease, osteomalacia, or any other metabolic bone disease;
10. Osteopenia or Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a dual energy x-ray absorptiometry (DXA) bone mineral density measurement. If DXA is required, exclusion will be defined as a DXA bone density measured T score less than or equal to -1.0.
11. Morbid obesity defined as a body mass index > 40 kg/m2 or weight more than 100 pounds over ideal body weight;
12. Active malignancy. A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless treated with curative intent and there has been no clinical signs or symptoms of the malignancy for more than 5 years;
13. Current or recent history (within last 2 years) of substance abuse (e.g., recreational drugs, narcotics, or alcohol);
14. Pregnant or planning to become pregnant during study period;
15. Involved in study of another investigational product that may affect outcome;
16. History of psychosocial disorders that could prevent accurate completion of self reporting assessment scales;
17. Patients who are incarcerated.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
chronOS Strip	chronOS Strip	This is a single arm, outcome study for treatment of patients with degenerative disc disease (DDD), with or without stenosis, with interbody fusion, posterolateral pedicle screw system, and the study device (chronOS Strip).

Primary Outcome Measures

Name	Time	Method
Posterolateral Fusion Success	Month 24	The primary outcome for posterolateral fusion status was a composite endpoint incorporating posterior bridging bone status, intersegmental motion (angular and translational motion) and posterior hardware status. To have successful posterolateral fusion, a subject had to be successful in all four components at all levels under investigation. Failure to meet any one of the four components indicated failed posterolateral fusion status.

Secondary Outcome Measures

Name	Time	Method
Percent Change in Oswestry Disability Index (ODI)	Month 24	The Oswestry Low Back Pain Disability Questionnaire was self-administered to each subject preoperatively and at each clinical follow up examination. Each of the ten questions had six ordered responses coded on a scale from zero to five. The scale ranges from 0-100. A higher score indicates a higher level of disability, and a negative percent change (post surgery minus baseline) indicates improved function. Percent change in ODI score was calculated as: \[(Month 24-Baseline)/Baseline\]\*100%.
Oswestry Disability Index (ODI)	Month 24	The Oswestry Low Back Pain Disability Questionnaire was self-administered to each subject preoperatively and at each clinical follow up examination. Each of the ten questions had six ordered responses coded on a scale from zero to five. The scale ranges from 0-100. A higher score indicates a higher level of disability, and a negative percent change (post surgery minus baseline) indicates improved function.
Percent Change in Back Pain on Visual Analog Scale	Month 24	The subjects completed questionnaires assessing the intensity of pain experienced in the back at the preoperative visit and at all visits postoperatively. Pain intensity was rated on a scale where zero indicated no pain, and 100 represented the worst possible pain. A negative change (post surgery minus baseline) indicated an improvement. Percent change was calculated as: \[(Month 24-Baseline)/Baseline\]\*100%.
Back Pain on Visual Analog Scale	Month 24	The subjects completed questionnaires assessing the intensity of pain experienced in the back at the preoperative visit and at all visits postoperatively. Pain intensity was rated on a scale where zero indicated no pain, and 100 represented the worst possible pain.
Short Form 12 (SF-12v2) Physical Component Summary (PCS)	Month 24	The SF-12v2, comprising 12 questions related to health and wellbeing over the prior four weeks, was administered to subjects preoperatively and at all follow up visits. SF-12v2 represents overall subjective health status by measuring eight health-related parameters (each scored from 0 \[poor health\] to 100 \[better health\]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. First, the eight scales were standardized using means and standard deviations (SD) for the general US population. Second, PCS was scored by aggregating the eight scales using a standardized algorithm. Finally, PCS was standardized using a linear t-score transformation to have a mean of 50 and a SD of 10 in the general US population (expected range: 13-69).
Percent Change in Short Form 12 (SF-12v2) Mental Component Summary (MCS)	Month 24	The SF-12v2, comprising 12 questions related to health and wellbeing over the prior four weeks, was administered to subjects preoperatively and at all follow up visits. SF-12v2 represents overall subjective health status by measuring eight health-related parameters (each scored from 0 \[poor health\] to 100 \[better health\]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. First, the eight scales were standardized using means and standard deviations (SD) for the general US population. Second, MCS was scored by aggregating the eight scales using a standardized algorithm. Finally, MCS was standardized using a linear t-score transformation to have a mean of 50 and a SD of 10 in the general US population (expected range: 10-70). Percent change was calculated as \[(Month 24 - Baseline)/Baseline\]\*100%.
Leg Pain on Visual Analog Scale	Month 24	The subjects completed questionnaires assessing the intensity of pain experienced in the leg at the preoperative visit and at all visits postoperatively. Pain intensity was rated on a scale where zero indicated no pain, and 100 represented the worst possible pain.
Percent Change in Leg Pain on Visual Analog Scale	Month 24	The subjects completed questionnaires assessing the intensity of pain experienced in the leg at the preoperative visit and at all visits postoperatively. Pain intensity was rated on a scale where zero indicated no pain, and 100 represented the worst possible pain. A negative change (post surgery minus baseline) indicated an improvement. Percent change was calculated as: \[(Month 24-Baseline)/Baseline\]\*100%.
Percent Change in Short Form 12 (SF-12v2) Physical Component Summary (PCS)	Month 24	The SF-12v2, comprising 12 questions related to health and wellbeing over the prior four weeks, was administered to subjects preoperatively and at all follow up visits. SF-12v2 represents overall subjective health status by measuring eight health-related parameters (each scored from 0 \[poor health\] to 100 \[better health\]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. First, the eight scales were standardized using means and standard deviations (SD) for the general US population. Second, PCS was scored by aggregating the eight scales using a standardized algorithm. Finally, PCS was standardized using a linear t-score transformation to have a mean of 50 and a SD of 10 in the general US population (expected range: 13-69). Percent change was calculated as \[(Month 24 - Baseline)/Baseline\]\*100%.
Short Form 12 (SF-12v2) Mental Component Summary (MCS)	Month 24	The SF-12v2, comprising 12 questions related to health and wellbeing over the prior four weeks, was administered to subjects preoperatively and at all follow up visits. SF-12v2 represents overall subjective health status by measuring eight health-related parameters (each scored from 0 \[poor health\] to 100 \[better health\]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. First, the eight scales were standardized using means and standard deviations (SD) for the general US population. Second, MCS was scored by aggregating the eight scales using a standardized algorithm. Finally, MCS was standardized using a linear t-score transformation to have a mean of 50 and a SD of 10 in the general US population (expected range: 10-70).

Trial Locations

Locations (13)

Hartford Hospital; 🇺🇸 Hartford, Connecticut, United States

Bay Area Neurosurgery; 🇺🇸 Brandon, Florida, United States

The Boston Spine Group; 🇺🇸 Newton, Massachusetts, United States

Atlanta Neurosurgical Associates; 🇺🇸 Decatur, Georgia, United States

Northwestern University; 🇺🇸 Chicago, Illinois, United States

The Rothman Institute; 🇺🇸 Philadelphia, Pennsylvania, United States

Southern New York Neurosurgical Group; 🇺🇸 Johnson City, New York, United States

University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

UPMC Presbyterian Dept. of Neurosurgery; 🇺🇸 Pittsburgh, Pennsylvania, United States

Orthopaedic and Spine Center; 🇺🇸 Newport News, Virginia, United States

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

Vanderbilt University Medical Center Department of Neurosurgery/Spine Research; 🇺🇸 Nashville, Tennessee, United States

University of Kansas Medical Center; 🇺🇸 Kansas City, Kansas, United States